Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica

Jennifer Keiser, Jürg Utzinger, Jonathan L. Vennerstrom, Yuxiang Dong, Gerry Brennan, Ian Fairweather

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Triclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a five-fold higher dose yielded a significant worm burden reduction of 60.9%. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3%. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.

Original languageEnglish (US)
Pages (from-to)1219-1222
Number of pages4
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume101
Issue number12
DOIs
StatePublished - Dec 1 2007

Fingerprint

triclabendazole
Fasciola hepatica
Fascioliasis
Pharmaceutical Preparations
artemether

Keywords

  • Artemether
  • Fasciola hepatica
  • OZ78
  • Oberon isolate
  • Resistance
  • Triclabendazole

ASJC Scopus subject areas

  • Parasitology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. / Keiser, Jennifer; Utzinger, Jürg; Vennerstrom, Jonathan L.; Dong, Yuxiang; Brennan, Gerry; Fairweather, Ian.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 101, No. 12, 01.12.2007, p. 1219-1222.

Research output: Contribution to journalArticle

@article{2c6dfbab8e8641baaa567b4b1ab6ab65,
title = "Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica",
abstract = "Triclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100{\%}. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0{\%}, a five-fold higher dose yielded a significant worm burden reduction of 60.9{\%}. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3{\%}. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.",
keywords = "Artemether, Fasciola hepatica, OZ78, Oberon isolate, Resistance, Triclabendazole",
author = "Jennifer Keiser and J{\"u}rg Utzinger and Vennerstrom, {Jonathan L.} and Yuxiang Dong and Gerry Brennan and Ian Fairweather",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.trstmh.2007.07.012",
language = "English (US)",
volume = "101",
pages = "1219--1222",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica

AU - Keiser, Jennifer

AU - Utzinger, Jürg

AU - Vennerstrom, Jonathan L.

AU - Dong, Yuxiang

AU - Brennan, Gerry

AU - Fairweather, Ian

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Triclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a five-fold higher dose yielded a significant worm burden reduction of 60.9%. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3%. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.

AB - Triclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a five-fold higher dose yielded a significant worm burden reduction of 60.9%. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3%. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.

KW - Artemether

KW - Fasciola hepatica

KW - OZ78

KW - Oberon isolate

KW - Resistance

KW - Triclabendazole

UR - http://www.scopus.com/inward/record.url?scp=35748941249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748941249&partnerID=8YFLogxK

U2 - 10.1016/j.trstmh.2007.07.012

DO - 10.1016/j.trstmh.2007.07.012

M3 - Article

C2 - 17905370

AN - SCOPUS:35748941249

VL - 101

SP - 1219

EP - 1222

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 12

ER -